Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 1/2015

01.04.2015 | short review

Optimal follow-up of cervical cancer patients

verfasst von: MD, PhD Eduard Vrdoljak, MD, PhD Tihana Boraska Jelavić, MD, PhD Branka Petrić Miše, MD, PhD Tomislav Omrčen

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten
share
TEILEN

Abstract

Gynecological malignancies account for round 10 % of all female cancers, with the cervical cancer being one of the major women health problems in developing regions of the world. Surveillance programs of cervical cancer are primarily based on recurrence rates, timing of recurrence, salvage options, and chances for curing patients with recurrence. Since there is no prospective, high evidence data about optimal surveillance program after primary treatment of patients with cervical cancer recommendations are based on the review of retrospective data sets. Literature search on this topic showed that there is no proven survival benefit for any follow-up schedule. Counseling the patients about early possible signs and symptoms of recurrent disease is of great importance. From all the diagnostic tools available, history taking and clinical examination, including comprehensive gynecological examination, still contribute to the greatest number of recurrence detection. Chest radiograph and computed tomography of abdomen and pelvis could be done in high-risk patients taking into account initial stage of the disease, previous treatment, symptom status, and local findings in order to detect potentially salvageable recurrences. Otherwise, radiologic tests are usually employed when a suspicion of recurrence is raised. Follow-up plan should be tailored according to estimated risk of relapse for individual patient.
Literatur
1.
Zurück zum Zitat Lanceley A, Fiander A, McCormack M, Bryant A. Follow-up protocols for women with cervical cancer after primary treatment. Cochrane Database Syst Rev 2013;(11). Art. No.:CD008767. doi:10.1002/14651858.CD008767.pub2. Lanceley A, Fiander A, McCormack M, Bryant A. Follow-up protocols for women with cervical cancer after primary treatment. Cochrane Database Syst Rev 2013;(11). Art. No.:CD008767. doi:10.1002/14651858.CD008767.pub2.
2.
Zurück zum Zitat American Cancer Society: cancer facts and figures 2014. Atlanta, Ga: American Cancer Society; 2014. American Cancer Society: cancer facts and figures 2014. Atlanta, Ga: American Cancer Society; 2014.
3.
Zurück zum Zitat Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17(5):1339–48. PubMed Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17(5):1339–48. PubMed
4.
Zurück zum Zitat Peters WA, Liu PY, Barret RJ 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18(8):1606–13. PubMed Peters WA, Liu PY, Barret RJ 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18(8):1606–13. PubMed
5.
Zurück zum Zitat Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340(15):1137–43. CrossRefPubMed Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340(15):1137–43. CrossRefPubMed
6.
Zurück zum Zitat Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340(15):1144–53. CrossRefPubMed Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340(15):1144–53. CrossRefPubMed
7.
Zurück zum Zitat Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340(15):1154–61. CrossRefPubMed Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340(15):1154–61. CrossRefPubMed
8.
Zurück zum Zitat Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix and endometrium. Int J Gynaecol Obstet. 2009;105:103–4. CrossRefPubMed Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix and endometrium. Int J Gynaecol Obstet. 2009;105:103–4. CrossRefPubMed
10.
Zurück zum Zitat Elit L, Fyles AW, Devries MC, Oliver TK, Fung-Kee-Fung M. Follow-up for women after treatment for cervical cancer: a systematic review. Gynecol Oncol. 2009;114:528–35. CrossRefPubMed Elit L, Fyles AW, Devries MC, Oliver TK, Fung-Kee-Fung M. Follow-up for women after treatment for cervical cancer: a systematic review. Gynecol Oncol. 2009;114:528–35. CrossRefPubMed
11.
Zurück zum Zitat Mangler M, Lanowska M, Kohler C, Vercellino F, Schneider A, Speiser D. Pattern of cancer recurrence in 320 patients after radical vaginal trachelectomy. Int J Gynecol Cancer. 2014;29(1):130–4. CrossRef Mangler M, Lanowska M, Kohler C, Vercellino F, Schneider A, Speiser D. Pattern of cancer recurrence in 320 patients after radical vaginal trachelectomy. Int J Gynecol Cancer. 2014;29(1):130–4. CrossRef
12.
Zurück zum Zitat Tanaka S, Nagase S, Kaiho-Sakuma M, et al. Clinical outcome of pelvic exenteration in patients with advanced or recurrent uterine cervical cancer. Int J Clin Oncol. 2014;19:133–8. CrossRefPubMed Tanaka S, Nagase S, Kaiho-Sakuma M, et al. Clinical outcome of pelvic exenteration in patients with advanced or recurrent uterine cervical cancer. Int J Clin Oncol. 2014;19:133–8. CrossRefPubMed
13.
Zurück zum Zitat Mabuchi S, Isohashi F, Maruoka S, et al. Post-treatment follow-up procedures in cervical cancer patients previously treated with radiotherapy. Arch Gynecol Obstet. 2012;286:179–85. CrossRefPubMed Mabuchi S, Isohashi F, Maruoka S, et al. Post-treatment follow-up procedures in cervical cancer patients previously treated with radiotherapy. Arch Gynecol Obstet. 2012;286:179–85. CrossRefPubMed
14.
Zurück zum Zitat Sartori E, Passinetti B, Carrara L, Gambino A, Odicino F, Pecorelli S. Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients. Gynecol Oncol. 2007;107:S241–7. CrossRefPubMed Sartori E, Passinetti B, Carrara L, Gambino A, Odicino F, Pecorelli S. Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients. Gynecol Oncol. 2007;107:S241–7. CrossRefPubMed
15.
Zurück zum Zitat Bodurka-Bevers D, Morris M, Eifel PJ, et al. Posttherapy surveillance of women with cervical cancer: an outcome analysis. Gynecol Oncol. 2000;78:187–93. CrossRefPubMed Bodurka-Bevers D, Morris M, Eifel PJ, et al. Posttherapy surveillance of women with cervical cancer: an outcome analysis. Gynecol Oncol. 2000;78:187–93. CrossRefPubMed
16.
Zurück zum Zitat Soisson AP, Geszler G, Soper JT, et al. A comparison of symptomatology, physical examination, and vaginal cytology in detection of recurrent cervical carcinoma after radical hysterectomy. Obstet Gynecol. 1990;76:106–9. PubMed Soisson AP, Geszler G, Soper JT, et al. A comparison of symptomatology, physical examination, and vaginal cytology in detection of recurrent cervical carcinoma after radical hysterectomy. Obstet Gynecol. 1990;76:106–9. PubMed
17.
Zurück zum Zitat Salani R, Backes FJ, Fung Kee Fung M. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol. 2011;204(6): 466–78. Salani R, Backes FJ, Fung Kee Fung M. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol. 2011;204(6): 466–78.
18.
Zurück zum Zitat Samlal RA, Van Der Velden J, Van Eerden T, Schilthuis MS, Gonzalez Gonzalez D, Lammes FB. Reccurent cervical carcinoma after radical hysterectomy: an analysis of clinical aspects and prognosis. Int J Gynecol Cancer. 1998;8:78–84. CrossRefPubMed Samlal RA, Van Der Velden J, Van Eerden T, Schilthuis MS, Gonzalez Gonzalez D, Lammes FB. Reccurent cervical carcinoma after radical hysterectomy: an analysis of clinical aspects and prognosis. Int J Gynecol Cancer. 1998;8:78–84. CrossRefPubMed
19.
Zurück zum Zitat Lim KC, Howells RE, Evans AS. The role of clinical follow up in early stage cervical cancer in South Wales. BJOG: Int J Obstet Gynaecol. 2004;111(2):1444–8. CrossRef Lim KC, Howells RE, Evans AS. The role of clinical follow up in early stage cervical cancer in South Wales. BJOG: Int J Obstet Gynaecol. 2004;111(2):1444–8. CrossRef
20.
Zurück zum Zitat Kim SH, Han MC. Invasion of the urinary bladder by uterine cervical carcinoma: evaluation with MR imaging. AJR Am J Roentgenol. 1997;168:393–7. CrossRefPubMed Kim SH, Han MC. Invasion of the urinary bladder by uterine cervical carcinoma: evaluation with MR imaging. AJR Am J Roentgenol. 1997;168:393–7. CrossRefPubMed
21.
Zurück zum Zitat Havrilesky LJ, Kulasingam SL, Matchar DB, et al. FDG-PET for management of cervical and ovarian cancer. Gynecol Oncol. 2005;97:183–91. CrossRefPubMed Havrilesky LJ, Kulasingam SL, Matchar DB, et al. FDG-PET for management of cervical and ovarian cancer. Gynecol Oncol. 2005;97:183–91. CrossRefPubMed
22.
Zurück zum Zitat Auguste P, Barton P, Meads C, et al. Evaluating PET-CT in routine surveillance and follow-up after treatment for cervical cancer: a cost-effectiveness analysis. BJOG. 2014;121:464–76. CrossRefPubMed Auguste P, Barton P, Meads C, et al. Evaluating PET-CT in routine surveillance and follow-up after treatment for cervical cancer: a cost-effectiveness analysis. BJOG. 2014;121:464–76. CrossRefPubMed
23.
Zurück zum Zitat Colombo N, Carinelli S, Colombo A, Marini C, Rollo D, Sessa C. Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23:vi27–32. Colombo N, Carinelli S, Colombo A, Marini C, Rollo D, Sessa C. Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23:vi27–32.
Metadaten
Titel
Optimal follow-up of cervical cancer patients
verfasst von
MD, PhD Eduard Vrdoljak
MD, PhD Tihana Boraska Jelavić
MD, PhD Branka Petrić Miše
MD, PhD Tomislav Omrčen
Publikationsdatum
01.04.2015
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2015
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-015-0203-y

Weitere Artikel der Ausgabe 1/2015

memo - Magazine of European Medical Oncology 1/2015 Zur Ausgabe